Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.

AIDS (London, England) - 12 Sept 2008

Delaugerre Constance, Pavie Juliette, Palmer Pierre, Ghosn Jade, Blanche Stephane, Roudiere Laurent, Dominguez Stephanie, Mortier Emmanuel, Molina Jean-Michel, de Truchis Pierre

Abstract excerpt

BACKGROUND: Ritonavir-boosted darunavir (DRV/r) has proven potent efficacy when used in heavily pretreated patients, harboring protease inhibitor-associated resistance mutations. Limited data are available on resistance pattern emerging in patients failing DRV/r and on subsequent remaining protease inhibitor options. METHODS: Analysis of baseline and failure resistance genotypes were performed in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to Darunavir

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease Inhibitors

Share to Pyridines

Share to Pyrones

Share to Sulfonamides

Share to Treatment Failure

Share to Viral Load

Source

Identifiers

PMID: 18690163
DOI: 10.1097/QAD.0b013e328307f24a

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.PMID 18690163Read ↗

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.Semantic proximity Read ↗

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.Semantic proximity Read ↗

Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.Semantic proximity Read ↗

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.Semantic proximity Read ↗

HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries.Semantic proximity Read ↗

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).Semantic proximity Read ↗

A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance.Semantic proximity Read ↗

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance MutationsSemantic proximity Read ↗

HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.Semantic proximity Read ↗

Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.Semantic proximity Read ↗

Prevalence of Darunavir Resistance in the United States from 2010 to 2017.Semantic proximity Read ↗

Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.